Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:activities |
inhibits complement activation
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2007
gptkb:FDA |
| gptkbp:class |
gptkb:drug
biologic therapy |
| gptkbp:clinical_trial |
Phase III
long-term management NC T00119824 NC T00704834 NC T01972487 NC T02021212 NC T02255678 chronic treatment preventative therapy |
| gptkbp:contraindication |
hypersensitivity to eculizumab
active meningococcal infection |
| gptkbp:developed_by |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:formulation |
liquid solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
eculizumab
|
| gptkbp:indication |
muscle weakness
hemolytic anemia thrombotic microangiopathy |
| gptkbp:ingredients |
C6484 H10000 N1716 O2000 S46
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
signs of infection
meningococcal vaccination status |
| gptkbp:is_used_for |
treatment of paroxysmal nocturnal hemoglobinuria
treatment of atypical hemolytic uremic syndrome treatment of generalized myasthenia gravis |
| gptkbp:manager |
intravenous
|
| gptkbp:marketed_as |
gptkb:Soliris
gptkb:legislation gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
complement inhibition
long half-life steady-state concentration achieved after multiple doses |
| gptkbp:price |
high
|
| gptkbp:research_areas |
neurology
autoimmune diseases hematology |
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
fatigue
headache nausea hypertension increased risk of infections thrombocytopenia infusion reactions serious infections |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
complement protein C5
|
| gptkbp:weight |
148,000 Da
|
| gptkbp:bfsParent |
gptkb:Soliris
gptkb:C5 |
| gptkbp:bfsLayer |
5
|